Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates – A multicenter cohort study

• Published in: Leukemia research 2020-02, Vol.89, p.106287-106287, Article 106287
• Main Authors: Silva, Wellington F. da, Garibaldi, Pedro Manoel Marques, Rosa, Lidiane Inês da, Bellesso, Marcelo, Clé, Diego Villa, Delamain, Márcia Torresan, Rego, Eduardo Magalhães, Pereira, Juliana, Rocha, Vanderson
• Format: Article
• Language: English
• Subjects: AIDS-related lymphoma; Burkitt Lymphoma; Chemotherapy; Developing countries; Survival
• ISSN: 0145-2126; 1873-5835
• DOI: 10.1016/j.leukres.2019.106287

•Few reports on HIV-associated Burkitt lymphoma are available from developing world.•Advanced disease was more frequent and 52% had a CD4+ lower than 200 cells/mm3.•Treatment-related mortality of 39% was found. Overall survival was 40% at 4 years.•Early mortality and toxicity were higher in our cohort than in developed countries. Although the increased use of combined antiretroviral therapy (cART) has decreased the incidence of lymphomas HIV-associated, Burkitt lymphoma (BL) incidence remains stable. Reported outcomes on HIV-associated BL from developed countries seem to corroborate that the regimens do not need to be tailored to the HIV-positive population. This is a retrospective multicenter cohort study from Brazil, including HIV-positive patients aged 15 years and above diagnosed with BL. A total of 54 patients were included. Median age was 39 years (range, 15–64). At diagnosis, advanced disease was found in 86% and 52% had a CD4+ count lower than 200 cells/mm3. Five patients died before starting any regimen. Among the remaining 49 patients, most were treated with Hyper-CVAD (53%) and CODOX-M IVAC (18%). Rituximab was used in frontline in only 16% of the patients. Primary refractory disease was found in 14%. A treatment-related mortality of 38.7% and a complete response rate of 44.9% were found. At 4 years, estimated overall survival (OS) was 39.8%. All relapsed and primary refractory patients eventually died. Remaining patients died from infections (24/34), despite antimicrobial prophylaxis and associated cART. Early mortality and toxicity were higher in our cohort than in developed countries. A faster diagnosis, better understanding of the biology of the disease, establishment of low toxicity regimens, inclusion of rituximab and improvement of supportive care may decrease the mortality of HIV-associated BL in developing countries.